Lunai Bioworks Inc. LNAI
Lunai Bioworks Inc. (Nasdaq: LNAI) is an oncology drug developer. Its lead program, RENB-DC11 (allogeneic dendritic cell vaccine), is in Pre-clinical for solid tumors, initially pancreatic cancer.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| RENB-DC11 | solid tumors (pancreatic) | cell therapy | Pre-clinical |
| RENB-DC20 | triple negative breast cancer | cell therapy | Pre-clinical |
| RENB-HV-12 | HIV vaccine (patent application only) | cell therapy | Pre-clinical |
| BioS_831 | epilepsy (mouse seizure model efficacy) | small molecule | Pre-clinical |
| Alcohol use disorder and CDKL5 epilepsy discovery programs | AUD; CDKL5 deficiency epilepsy | small molecule | Pre-clinical |
| N2B nose-to-brain platform / Alzheimer's compound | biodefense countermeasures; Alzheimer's disease | unclear | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
- Legend Biotech Corp LEGN
- Veracyte, Inc. VCYT
- Indaptus Therapeutics, Inc. INDP
- SL Science Holding Ltd SLBT
- YD Bio Ltd YDES
- OnKure Therapeutics, Inc. OKUR
- Boundless Bio, Inc. BOLD
- NextCure, Inc. NXTC
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.